Member Info for Serge1

Nice drop to take advantage of

Good few months coming up
Q4…
- FDA 510k submission
- EACTS conference (surgeon carrying out assessment of graft) Feedback following conference

Q1…
- FDA approval
- Launch of product
- Confirmation of distribution partners

Q2…
- Significant scaling up of product

Anyone looked at EISB?

Look like a very decent competitor for fever in the long time. Good story. I’ve moved some profits from here into there

Amazing brand, great product, brilliant ethos.

This will be £100m market cap by the end of the year. Once the Q4 expansion plans have all come into play and further deals land. Very excited by this play and it’s only just the beginning.

I’m expecting further TR1s tomorrow, placing flipping to dry up and a strong move forward.
A huge chunk of this stock is being held tightly - gut feeling is we are getting close to a deal being done and it’s essentially just final formalities.

Interesting week upon us.

Evening all, just thought I’d write to clear up a few things in regards to the MAC vs here.

Firstly, it’s common knowledge that Chris presented the board with an opportunity and the board decline, hence CA then selling his entire holding - which he is entitled to do.

Now, the difference being here is the board - we have Simon of AAA and John Taylor of Low6/ASLR. They already have significant relationships with Akers, this is his board of choice.

Also, CA is sweeping up in the open market. Moved from 9% to 15% in a few days - and something tells me he is buying more.

Someone made a great comment below in regards to trust - Akers has an incredible following at the moment, another MAC scenario would faint that. However..

When I look at QTZ I see AAA and DEV.
When some look at QTZ, they are MAC.

https://ichrom.com/wp-content/uploads/2019/09/07_App-note-11-Cannabinoids-and-TLC-MS.pdf

And the wording refers to the accelerated drilling and exploration due to the JV this year. I thought that was obvious..

Disappointed in you Dibs, you’re normally level headed.

Great target, without even looking at the JV as a catalyst.

It’s looking very strong here early 2021. January should be exciting.

https://zakmir.com/stock-market-watch-avct-brh-far-kat-kibo-phe-rms-tils-vls-vlu/#gs.l91ko4

The public free float is already tiny, it would be madness for him to buy on the open market. We have been NT between 8-10am both days this week

I expect even longer unfortunately

Really enjoyed the webinar tonight lots to get excited about. Kunwar does come across very well and likeable.
Some of the questions from Yanks were terrible but food to see him answering well. Some good UK questions, great questions from Jordan and others.

Expecting a big blue day tomorrow
Hopefully manipulation in US stops

What the hell is going on. I literally can’t keep up.

Fair to say, this will make a great Netflix series when it finally concludes.

Whatever happened to Looed and the letter he was going to send to the solicitors?

....been doing this 6 months ago - considering we are just over a month away from an election, no harm in holding off a few more days/weeks.

It is Looed's perogative, and I certainly wouldn't be bashing him for this, as he's actually doing something productive, however if there was vote - I would vote to send it out shortly after the election.

I’ve been told elsewhere that results are known now between all. Patients informed. Which I assume means the company are now free to release.

Are you able to contact those two again? I do wonder if this new person has come out due to being told they were infect on Blautix. But could be complete crap as you say.

Either way, not long to wait now.

Are you able to expand on what was discussed?

What date is that from?

Yes that's always a bitter read but let's brake down the numbers. Generally the Phase 2 to Phase 3 success rate, which means the chance that a drug which has entered Phase 2 will later also enter Phase 3 is just north of 30%. This tragic number however takes into account all kinds of discontinuations, so failures of safety and efficacy of course but also a lack of funding, bankruptcy, lack of interest and all other reasons why development might not be pursued.

Now for Drugs in gastroenterology the success rate is a bit higher fortunately, but perhaps most importantly the drugs you see in the list above have some individual peculiarities which shift the potential for success more into the positive. SYN-010, MD-7246 and Aemcolo are already approved and on the market which substantially lessens their safety concerns compared to an entirely new compound. Vibegron has cleared several other clinical trials and IBS is the 3rd indication. So far results have been solid and therefore approval is also more likely. Olorinab has already cleared Phase 2a trials and BOS-589 has very little systemic uptake, but this is something we should not take into account at this point.

Out of these 7x0.3=2.1 will make it into Phase 3 if we're conservative. Because so many of them have a favorable filing situation (505(B)2 has a much higher success rate) in an optimistic scenario I'd say we can allow ourselves to dream of 3 out of 7. Anything more than that would be astonishing.

Interesting read, also taken from Reddit.

From a few weeks ago

We are still waiting for the topline results which will be presented in Q3, for now the interim analysis showed that Blautix was safe and well tolerated, with a similar (almost identical) adverse events profile to placebo. Preliminary efficacy data also shows the effect to be "not futile" which is encouraging. Let's hope the efficacy is substantial when the final results are released.